This issue of the journal showcases 3 clinical trials [1-3], each focused on testing the utility of industrially sourced culture-adapted allogeneic mesenchymal stromal cells (MSCs; remestemcel-L) as a transfusion product to improve the outcome of steroid-refractory acute graft-versus-host disease (GHVD).
No takes yet. Share an insight, caveat, or question.
Jacques Galipeau (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: